GOTEBORG, Sweden, September 1 /PRNewswire/ -- Calabar AB, a privately held pharmaceutical company developing therapies for treating dry mouth, today announced a EUR 350,000 equity financing from the investment company Karolinska Development AB. The financing will take Calabar's product through a phase II study with repeated dosing. "We believe the unique local action of the drug on the minor glands will lead to improved outcomes in patients with dry mouth and we look forward to its continued development," remarked VP Business Development, Fredrik Rook of Calabar AB. "Dry mouth is affecting millions of people every day and there is a great unmet need for new drugs in this area."
The active drug, physostigmine, a cholinesterase inhibitor, targets the minor salivary glands with a direct local action, inducing a more lubricating saliva. In previous phase II studies with single dosing, the locally administered drug proved to significantly increase the salivary flow in patients suffering from dry mouth.
"This will take treatment of dry mouth symptoms to a new level," concludes Mr. Rook.
About Calabar
Calabar AB is a privately-held company committed to developing a pharmaceutical product addressing the great unmet needs of xerostomia "dry mouth". The company develops locally administered formulations of the cholinesterase inhibitor physostigmine, which has been shown to effectively increase salivary flow. Unlike systemically administered drugs, the local route of administration significantly limits adverse events. The company is part of the Karolinska Development AB portfolio. For more information, please visit http://www.calabar.se
CONTACT: Investor and Media Contact: Fredrik Rook, +46-8-524-860-38,
fredrik.rook@calabar.se .
